Full Text View
Tabular View
No Study Results Posted
Related Studies
Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons
This study is not yet open for participant recruitment.
Verified by University of Sao Paulo, January 2007
First Received: May 30, 2007   No Changes Posted
Sponsored by: University of Sao Paulo
Information provided by: University of Sao Paulo
ClinicalTrials.gov Identifier: NCT00481351
  Purpose

Efects of statin and ezetimibe association on kinetics of artificial chylomicrons in men with stable coronary heart disease (CHD).

Background:

The rate (kinetics) of chylomicrons removal from circulation have been correlated with the incidence and severity of atherosclerotic lesions; a number of studies demonstrated lower plasmatic clearance of chylomicrons in patients with CHD compared to patients without this condition. It was also demonstrated a correlation among LDL-C levels and removal of chylomicrons remnants by a technique employing artificial chylomicrons.

We also know that higher doses of more potent statins are more effective in chylomicrons removal than lower doses or less potent statins; nevertheless, the effect of the isolated use of statin has not been completely studied up to now.

Study design:

We propose to study 26 outpatients volunteers with chronic CHD, followed at the Heart Institute - INCOR - of the School of Medicine, University of São Paulo. Following a period of six weeks of washout from any cholesterol reducer, the kinetics of chylomicrons removal by a technique of emulsion of radiolabeled artificial chylomicrons will be evaluated. Lipid fractions, hepatic enzymes and CK will be measured. Initially patients will be randomly allocated to receive simvastatin 20 mg /day (n= 13) or ezetimibe 10 mg/day (n=13) for six weeks. At the end of this period, kinetics of chylomicrons removal and laboratorial measurements will be repeated (Period 1). In the next period (Period 2) patients will receive simvastatin 20 mg/ ezetimibe 10 mg (n=13) or simvastatin 80 mg (n=13) for additional six weeks; at the end of this period, the evaluations will be repeated (third and last evaluation).

The aim of this study is to further understand chylomicrons metabolism in patients with chronic coronary disease receiving cholesterol reducers at different dosage regimes.


Condition Intervention Phase
Coronary Heart Disease
Drug: Sinvastatin plus ezetimibe
Phase IV

MedlinePlus related topics: Coronary Artery Disease Heart Diseases Statins
Drug Information available for: Ezetimibe
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study
Official Title: Effects of Statin and Ezetimibe Association on Kinetics of Artificial Chilomicrons in Men With Stable Coronary Heart Disease.

Further study details as provided by University of Sao Paulo:

Primary Outcome Measures:
  • Clearance rate of blood artificial chilomicrons after infusion of a radiolabeled artificial chylomicrons emulsion. [ Time Frame: 6 weeks ]

Study Start Date: June 2007
Estimated Study Completion Date: January 2009
  Eligibility

Ages Eligible for Study:   30 Years to 75 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Stable coronary heart disease.

Exclusion Criteria:

  • Renal and Liver failure
  • Hypothyroidism
  • Diabetes mellitus
  • Neoplasia
  • Heart failure.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00481351

Contacts
Contact: Otavio Mangili, Physician 554499225115 otaviomangili@yahoo.com.br

Sponsors and Collaborators
University of Sao Paulo
Investigators
Principal Investigator: Otavio Mangili, Physician University of Sao Paulo
  More Information

No publications provided

Study ID Numbers: 1068/06
Study First Received: May 30, 2007
Last Updated: May 30, 2007
ClinicalTrials.gov Identifier: NCT00481351     History of Changes
Health Authority: Brazil: National Committee of Ethics in Research

Keywords provided by University of Sao Paulo:
artificial chilomicrons kinetics
ezetimibe plus statin
lipid lowering therapy

Study placed in the following topic categories:
Arterial Occlusive Diseases
Antimetabolites
Heart Diseases
Myocardial Ischemia
Antilipemic Agents
Vascular Diseases
Ezetimibe
Ischemia
Arteriosclerosis
Anticholesteremic Agents
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Coronary Disease
Coronary Artery Disease

Additional relevant MeSH terms:
Arterial Occlusive Diseases
Antimetabolites
Heart Diseases
Molecular Mechanisms of Pharmacological Action
Myocardial Ischemia
Antilipemic Agents
Vascular Diseases
Ezetimibe
Arteriosclerosis
Anticholesteremic Agents
Pharmacologic Actions
Coronary Disease
Therapeutic Uses
Cardiovascular Diseases
Coronary Artery Disease

ClinicalTrials.gov processed this record on May 07, 2009